BioCentury | Mar 2, 2017
Finance

Drugging RNA

...introduction to Canaan came through Osage, which had previously co-invested with Advent in antibody company Capella BioScience Ltd....
BioCentury | Apr 4, 2016
Finance

Medicxi's platform exception

...Medicxi joined a syndicate to back an £11 million ($15.6 million) series A round for Capella BioScience Ltd....
BioCentury | Mar 14, 2016
Finance

Medicxi's antibody experiment

...single asset out of academia, the firm is part of a syndicate that is funding Capella BioScience Ltd....
BioCentury | Mar 14, 2016
Financial News

Capella Bioscience completes venture financing

Capella Bioscience Ltd. , London, U.K. Business: Cancer, Autoimmune Date completed: 2016-03-08 Type: Venture financing Raised: L11 million ($15.6 million) Investors: Advent Life Sciences; Medicxi Ventures; Osage University Partners WIR Staff autoimmune cancer...
BioCentury | Mar 9, 2016
Financial News

Capella raises L11 million series A

Capella Bioscience Ltd. (London, U.K.) raised L11 million ($15.6 million) in a tranched series A round with Advent Life Sciences, Medicxi Ventures and Osage University Partners. Capella's lead program is a first-in-class antibody that inhibits...
Items per page:
1 - 5 of 5
BioCentury | Mar 2, 2017
Finance

Drugging RNA

...introduction to Canaan came through Osage, which had previously co-invested with Advent in antibody company Capella BioScience Ltd....
BioCentury | Apr 4, 2016
Finance

Medicxi's platform exception

...Medicxi joined a syndicate to back an £11 million ($15.6 million) series A round for Capella BioScience Ltd....
BioCentury | Mar 14, 2016
Finance

Medicxi's antibody experiment

...single asset out of academia, the firm is part of a syndicate that is funding Capella BioScience Ltd....
BioCentury | Mar 14, 2016
Financial News

Capella Bioscience completes venture financing

Capella Bioscience Ltd. , London, U.K. Business: Cancer, Autoimmune Date completed: 2016-03-08 Type: Venture financing Raised: L11 million ($15.6 million) Investors: Advent Life Sciences; Medicxi Ventures; Osage University Partners WIR Staff autoimmune cancer...
BioCentury | Mar 9, 2016
Financial News

Capella raises L11 million series A

Capella Bioscience Ltd. (London, U.K.) raised L11 million ($15.6 million) in a tranched series A round with Advent Life Sciences, Medicxi Ventures and Osage University Partners. Capella's lead program is a first-in-class antibody that inhibits...
Items per page:
1 - 5 of 5